Review
Open access
Sep 2026
Beyond CAR-T: Preventing and Treating Relapse in B-Cell Haematological Malignancies
Current evidence remains largely preliminary and is limited by the paucity of randomized prospective trials, although relapse management is disease-specific and increasingly incorporates novel therapeutic agents, including bispecific antibodies (BsAbs) and other targeted therapies.
Martina Canichella, E. Abruzzese, Mariagiovanna Cefalo et al.
· Cells · 0 citations